//
sign in
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
Clinical trial results don’t usually get standing ovations—but Brian Wolpin and his team truly deserved their reception at #ASCO26. Seeing Phase 3 data on the impact of daraxonrasib in patients with advanced pancreatic cancer sent chills through the entire room. 🧵 www.theguardian.com/society/2026...
11d
www.theguardian.com
Experts hail daraxonrasib as ‘gamechanger’ for patients with advanced pancreatic cancer
Daily pill can double survival time for world’s deadliest cancer, trial shows
The Mark Foundation for Cancer Research